Establishment and characterization of circulating tumor cells-derived organoids from metastatic breast cancer patients.
Over the last decade, molecular stratification and associated therapies have greatly improved the treatment options and prognosis of patients diagnosed with breast cancer. However, metastatic disease remains incurable. Breast cancer cells mainly spread to the lung, liver, bone and brain and circulating tumor cells (CTCs) that migrate in the lymphatics or blood have been implicated as the cellular source of metastasis. Detailed molecular and functional characterization of patient CTCs remains poor due to their low number in patient’s bloodstream. In addition, CTCs are difficult to culture and expand ex vivo. Here we have established a novel method for culturing and unlimitedly expanding breast cancer patient-derived CTCs in CTC-derived organoids (CDOs). Our platform can serve as a foundation for serial longitudinal isolation and expansion of breast cancer cells from peripheral blood. This may enable the identification and functional validation of therapy resistance mechanisms during disease progression, which can be used for new approaches in precision medicine.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Publications | Citations |
---|---|
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling.
Nat Cancer 6: 2025 67-85 |
0 |